Embecta Corp

NASDAQ EMBC

Data sourced from iex and EODHD
Download Data

Embecta Corp Other Operating Expenses 3 year CAGR for the Trailing 12 Months (TTM) ending March 31, 2024

Embecta Corp Other Operating Expenses 3 year CAGR is NA for the Trailing 12 Months (TTM) ending March 31, 2024. Other Operating Expenses are any additional operating expenses that are not specifically categorized but still impact the company's profitability. CAGR, or the Compound Annual Growth Rate, quantifies the mean annual growth rate of an investment or financial metric over a specified time span, considering the influence of compounding. It is instrumental in determining the true annualized return on an investment.
  • Embecta Corp Other Operating Expenses for the Trailing 12 Months (TTM) ending March 31, 2023 was USD 41.70 M, a 211.19% change year over year.
  • Embecta Corp Other Operating Expenses for the Trailing 12 Months (TTM) ending March 31, 2022 was USD 13.40 M, a 0.00% change year over year.
  • Embecta Corp Other Operating Expenses for the Trailing 12 Months (TTM) ending March 31, 2021 was USD 0.00.
NASDAQ: EMBC

Embecta Corp

CEO Mr. Devdatt Kurdikar
IPO Date April 1, 2022
Location United States
Headquarters 300 Kimball Drive, Parsippany, NJ, United States, 07054
Employees 2,200
Sector Healthcare
Industry Medical instruments & supplies
Description

Embecta Corp., a medical device company, focuses on the provision of various solutions to enhance the health and wellbeing of people living with diabetes. Its products include pen needles, syringes, and safety injection devices, as well as digital applications to assist people with managing patient's diabetes. The company primarily sells its products to wholesalers and distributors in the United States and internationally. Embecta Corp. was founded in 1924 and is headquartered in Parsippany, New Jersey.

Similar companies

ANGO

AngioDynamics Inc

NA

NA

AKYA

Akoya Biosciences Inc

NA

NA

StockViz Staff

September 19, 2024

Any question? Send us an email